OTC:HEPA
Hepion Pharmaceuticals, Inc.
A clinical-stage biopharma firm advancing novel treatments for rare genetic disorders with a focus on expanding its pipeline through strategic partnerships.
Key Metrics
Investment Thesis
Bull Case
Early-stage biopharma investors may find value in the company's potential pipeline assets for rare diseases which could yield high returns upon successful FDA approval and commercialization, while the recent reduction in annual losses might indicate an inflection point toward profitability. Strategic partnerships or licensing deals could provide non-dilutive capital to offset the current cash burn.
Bear Case
With no revenue, a massive retained earnings deficit of $237.8M, and ending cash below half a million dollars, the company faces imminent bankruptcy risk without immediate successful fundraising or asset monetization. The negative operating cash flow of $18.2M combined with high general and administrative expenses of $7.5M creates a precarious financial position that makes equity investment highly speculative.
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies for rare diseases such as Fabry disease and spinal muscular atrophy. The company operates primarily in the United States and international markets, focusing on orphan drug development to address unmet medical needs.
Analysis
Management Discussion
The company reported a net loss of $13.2 million in 2024, down from previous years of -$48.9M and -$42.2M, suggesting an improvement in operational efficiency or reduced burn rate despite continued negative operating cash flow. However, the significant reduction in cash reserves from $14.8M to under $500K and a negative working capital change of $6.6M highlight severe liquidity pressures requiring immediate attention.
Industry Overview
The orphan drug sector is characterized by high R&D costs, long development timelines, and significant regulatory hurdles, yet offers the potential for substantial market exclusivity and pricing power once therapies gain approval. Companies in this space often rely on continuous capital raises to fund clinical trials before generating any commercial revenue.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $45.5M | $48.4M | $19.3M |
| Operating Income | $-45.5M | $-48.4M | $-19.3M |
| R&D | $33.3M | $35.6M | $11.8M |
| G&A | $10.3M | $9.6M | $7.5M |
| Stock-Based Comp | $2.6M | $1.3M | $791.6K |
| D&A | $77.5K | $67.1K | $30.8K |
| Depreciation | $100.0K | $100.0K | $100.0K |
| Other OpEx | $1.9M | $3.2M | $0 |
| Non-Operating Income | $404.8K | $-887.1K | $3.2M |
| Interest Expense | $10.2K | $9.5K | — |
| Pre-Tax Income | $-45.1M | $-49.3M | $-16.2M |
| Income Tax | $-2.9M | $-409.0K | $-3.0M |
| Continuing Ops | $-42.2M | $-48.9M | $-13.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-42.2M | $-48.9M | $-13.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-42.2M | $-48.9M | $-13.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $56.5M | $17.5M | $1.6M |
| Long-Term Assets | $3.7M | $606.6K | $0 |
| PP&E (Net) | $81.6K | $29.5K | — |
| Goodwill | $0 | — | — |
| Operating Leases | $50.6K | $212.9K | — |
| Other LT Assets | $3.6M | $364.2K | — |
| Total Assets | $60.2M | $18.1M | $1.6M |
| Current Liabilities | $7.9M | $5.3M | $3.1M |
| Accounts Payable | $2.7M | $2.3M | $220.2K |
| Current Leases | $53.6K | $115.9K | — |
| Other Current Liab | $366.2K | $386.0K | $2.9M |
| Long-Term Liabilities | $2.5M | $5.5M | $333.2K |
| LT Operating Leases | $0 | $93.1K | — |
| Other LT Liab | $2.5M | $5.4M | — |
| Total Liabilities | $10.4M | $10.8M | $3.5M |
| Shareholders' Equity | $49.9M | $7.3M | $-1.9M |
| Paid-In Capital | — | — | $234.3M |
| Retained Earnings | $-175.7M | $-224.6M | $-237.8M |
| AOCI | $-90.2K | $-78.8K | $8.3K |
| Total L&E | $60.2M | $18.1M | $1.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-42.2M | $-48.9M | $-13.2M |
| Non-Cash Adjustments | $6.2M | $10.1M | $1.6M |
| Working Capital Changes | $1.1M | $-2.1M | $-6.6M |
| Cash from Operations | $-35.0M | $-40.9M | $-18.2M |
| Capital Expenditures | $16.3K | $14.3K | — |
| Cash from Investing | $-14.1K | $-14.3K | $-600.0K |
| Debt Repayments | $0 | — | — |
| Cash from Financing | $-5.1M | $4.5M | $4.3M |
| FX Effect | $-47.1K | $5.0K | $87.1K |
| Net Change in Cash | $-40.2M | $-36.4M | $-14.4M |
| Beginning Cash | $91.3M | $51.2M | $14.8M |
| Ending Cash | $51.2M | $14.8M | $406.4K |
Frequently Asked Questions
How does Hepion Pharmaceuticals, Inc. make money?
The company's financial structure indicates a pre-revenue biopharmaceutical model reliant on research and development expenses and financing activities rather than traditional product sales revenue streams, with operations centered on drug discovery and clinical trial execution.
What are the main risks for HEPA?
Complete absence of commercial revenue leading to dependence on equity financing and grant funding, significant accumulated deficit indicating potential solvency challenges without new capital raises, substantial cash burn from R&D activities, and regulatory uncertainty surrounding orphan drug approvals.
What is HEPA's competitive advantage?
Access to novel molecular platforms for rare disease targets, potential for high-margin orphan drug approval pathways with market exclusivity, and a lean operational structure that minimizes current asset requirements while maximizing R&D capital allocation.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.